Page 95 - Read Online

Corn et al. J Cancer Metastasis Treat 2021;7:41 https://dx.doi.org/10.20517/2394-4722.2021.63 Page 17 of 19

Available from: https://seer.cancer.gov/csr/1975_2015/ [Last accessed on 3 Aug 2021].
64. Nayan S, Ramakrishna J, Gupta MK. The Proportion of malignancy in incidental thyroid lesions on 18-FDG PET study: a systematic
review and meta-analysis. Otolaryngol Head Neck Surg 2014;151:190-200. DOI PubMed
18
65. Millare GG, Kwon M, Edeiken-Monroe BS, Debnam JM. F-PET/CT imaging of metastasis to the thyroid gland: imaging findings
and effect on patient management. J Solid Tumors 2017;7:7-13. DOI PubMed PMC
66. Mitchell JC, Grant F, Evenson AR, Parker JA, Hasselgren PO, Parangi S. Preoperative evaluation of thyroid nodules with 18FDG-
PET/CT. Surgery 2005;138:1166-74; discussion 1174. DOI PubMed
67. Boeckmann J, Bartel T, Siegel E, Bodenner D, Stack BC Jr. Can the pathology of a thyroid nodule be determined by positron
emission tomography uptake? Otolaryngol Head Neck Surg 2012;146:906-12. DOI PubMed
68. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med 2007;48:932-45. DOI PubMed
18
69. Aksu A, Karahan Şen NP, Acar E, Çapa Kaya G. Evaluating focal F-FDG uptake in thyroid gland with radiomics. Nucl Med Mol
Imaging 2020;54:241-8. DOI PubMed PMC
70. Shi H, Yuan Z, Yuan Z, et al. Diagnostic value of volume-based fluorine-18-fluorodeoxyglucose PET/CT parameters for
characterizing thyroid incidentaloma. Korean J Radiol 2018;19:342-51. DOI PubMed PMC
71. Kim BH, Kim SJ, Kim H, et al. Diagnostic value of metabolic tumor volume assessed by 18F-FDG PET/CT added to SUVmax for
characterization of thyroid 18F-FDG incidentaloma. Nucl Med Commun 2013;34:868-76. DOI PubMed
18
72. Sollini M, Cozzi L, Pepe G, et al. [ F]FDG-PET/CT texture analysis in thyroid incidentalomas: preliminary results. Eur J Hybrid
Imaging 2017;1:3. DOI PubMed PMC
73. Bertagna F, Treglia G, Piccardo A, Giubbini R. Diagnostic and clinical significance of F-18-FDG-PET/CT thyroid incidentalomas. J
Clin Endocrinol Metab 2012;97:3866-75. DOI PubMed
74. Sager S, Vatankulu B, Sahin OE, et al. Clinical significance of standardized uptake values in thyroid incidentaloma discovered by F-
18 fluorodeoxyglucose positron emission tomography/computed tomography. J Cancer Res Ther 2018;14:989-93. DOI PubMed
75. Thuillier P, Bourhis D, Roudaut N, et al. Diagnostic Value of FDG PET-CT quantitative parameters and deauville-like 5 point-scale
in predicting malignancy of focal thyroid incidentaloma. Front Med (Lausanne) 2019;6:24. DOI PubMed PMC
76. Ho TY, Liou MJ, Lin KJ, Yen TC. Prevalence and significance of thyroid uptake detected by 18F-FDG PET. Endocrine
2011;40:297-302. DOI PubMed
77. Yang J, Kan Y, Ge BH, Yuan L, Li C, Zhao W. Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in
patients with neuroendocrine tumors: a meta-analysis. Acta Radiol 2014;55:389-98. DOI PubMed
78. Druckenthaner M, Schwarzer C, Ensinger C, et al. Evidence for somatostatin receptor 2 in thyroid tissue. Regul Pept 2007;138:32-9.
DOI PubMed
79. Prasad V, Ambrosini V, Alavi A, Fanti S, Baum RP. PET/CT in neuroendocrine tumors: evaluation of receptor status and
metabolism. PET Clin 2008;3:355-79. DOI PubMed
80. Ambrosini V, Nanni C, Fanti S. The use of gallium-68 labeled somatostatin receptors in PET/CT imaging. PET Clin 2014;9:323-9.
DOI PubMed
81. Atkinson H, England JA, Rafferty A, et al. Somatostatin receptor expression in thyroid disease. Int J Exp Pathol 2013;94:226-9. DOI
PubMed PMC
82. Kunikowska J, Matyskiel R, Zemczak A, et al. How often do we see incidental 68Ga-DOTATATE thyroid uptake in PET/CT in
patients with neuroendocrine tumours? Endokrynol Pol 2015;66:231-6. DOI PubMed
83. Kohlenberg JD, Panda A, Johnson GB, Castro MR. Radiologic and clinicopathologic characteristics of thyroid nodules with focal
68Ga-DOTATATE PET activity. Nucl Med Commun 2021;42:510-6. DOI PubMed
84. Beukhof CM, Brabander T, van Nederveen FH, et al. Peptide receptor radionuclide therapy in patients with medullary thyroid
carcinoma: predictors and pitfalls. BMC Cancer 2019;19:325. DOI PubMed PMC
85. Moore M, Panjwani S, Mathew R, et al. Well-differentiated thyroid cancer neovasculature expresses prostate-specific membrane
antigen-a possible novel therapeutic target. Endocr Pathol 2017;28:339-44. DOI PubMed
86. Verma P, Malhotra G, Agrawal R, Sonavane S, Meshram V, Asopa RV. Evidence of prostate-specific membrane antigen expression
in metastatic differentiated thyroid cancer using 68Ga-PSMA-HBED-CC PET/CT. Clin Nucl Med 2018;43:e265-8. DOI PubMed
68
87. Bertagna F, Albano D, Giovanella L, et al. Ga-PSMA PET thyroid incidentalomas. Hormones (Athens) 2019;18:145-9. DOI
PubMed
88. Gossili F, Petersen LJ, Zacho HD. The frequency of thyroid incidental findings and risk of malignancy detected by 68Ga-labeled
prostate-specific membrane antigen PET/CT in prostate cancer. Hell J Nucl Med 2020;23:240-5. DOI PubMed
89. Santhanam P, Cooper D. How should we approach incidental thyroid nodules with Gallium-68 Prostate-Specific Membrane Antigen
(PSMA) positivity? Clin Thyroidol 2021;33:87-91. DOI
90. Mertens K, Slaets D, Lambert B, Acou M, De Vos F, Goethals I. PET with (18)F-labelled choline-based tracers for tumour imaging:
a review of the literature. Eur J Nucl Med Mol Imaging 2010;37:2188-93. DOI PubMed
91. Treglia G, Giovannini E, Di Franco D, et al. The role of positron emission tomography using carbon-11 and fluorine-18 choline in
tumors other than prostate cancer: a systematic review. Ann Nucl Med 2012;26:451-61. DOI PubMed
92. Uslu-Beşli L, Sonmezoglu K, Teksoz S, et al. Performance of F-18 Fluorocholine PET/CT for detection of hyperfunctioning
parathyroid tissue in patients with elevated parathyroid hormone levels and negative or discrepant results in conventional imaging.
Korean J Radiol 2020;21:236-47. DOI PubMed PMC
93. Podo F. Tumour phospholipid metabolism. NMR Biomed 1999;12:413-39. DOI PubMed
94. Ruiz-Esponda RL, Dean DS. Clinical significance of incidental thyroid uptake on 11Ccholine PET/CT. Endo Rev 2014:35. DOI